nach oben

Erschienen in:

01.09.2008 | Original Paper

The PMAIP1 Gene on Chromosome 18 is a Candidate Tumor Suppressor Gene in Human Pancreatic Cancer

verfasst von: Masaharu Ishida, Makoto Sunamura, Toru Furukawa, Liviu P. Lefter, Rina Morita, Masanori Akada, Shinichi Egawa, Michiaki Unno, Akira Horii

Erschienen in: Digestive Diseases and Sciences | Ausgabe 9/2008

Einloggen, um Zugang zu erhalten

Abstract

Frequent loss of heterozygosity on the long arm of chromosome 18 is observed in pancreatic cancer. Previous studies suggested the existence of one or more tumor-suppressor genes other than SMAD4 on chromosome 18. To identify the candidate tumor-suppressor gene(s), we compared gene expression by cDNA microarray analyses using a pancreatic cancer cell line Panc-1 and its hybrid cell lines showing suppressed cell growth after introduction of one normal copy of chromosome 18. The microarray analyses identified 38 genes on chromosome 18 that showed differential expressional levels. Among these genes, phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1/APR/NOXA) was identified as one of the candidates for tumor suppressor. Expression vector-mediated introduction of PMAIP1 suppressed cell proliferation, and RNAi-mediated knockdown of PMAIP1 induced recovery of cell growth. These results suggest that PMAIP1 may play an important role in the progression of pancreatic cancer.

Nur mit Berechtigung zugänglich

Parker SL, Tong T, Bolden S, Wing PA (1997) Cancer statistics. CA Cancer J Clin 47:5–27PubMedCrossRef

Trede M, Schwall G, Saeger HD (1990) Survival after pancreatoduodenectomy. Ann Surg 211:447–458PubMedCrossRef

Livingston EH, Welton ML, Reber HA (1991) The United States’ experience with surgery for pancreatic cancer. Int J Pancreatol 9:153–157PubMed

Furukawa T, Sunamura M, Horii A (2006) Molecular mechanisms of pancreatic carcinogenesis. Cancer Sci 97:1–7PubMedCrossRef

Griffin CA, Hruban RH, Morsberger LA, Ellingham T, Long PP, Jaffee EM, Hauda KM, Bohlander SK, Yeo CJ (1995) Consistent chromosome abnormalities in adenocarcinoma of the pancreas. Cancer Res 55:2394–2399PubMed

Kimura M, Furukawa T, Sunamura M, Takeda K, Matsuno S, Horii A (1996) Detailed deletion mapping on chromosome arm 12q in human pancreatic adenocarcinoma: identification of a 1-cM region of common allelic loss. Genes Chromosomes Cancer 17:88–93PubMedCrossRef

Fukushige S, Waldman FM, Kimura M, Abe T, Furukawa T, Sunamura M, Kobari M, Horii A (1997) Frequent gain of copy number on the long arm of chromosome 20 in human pancreatic adenocarcinoma. Genes Chromosomes Cancer 19:161–169PubMedCrossRef

Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M (1988) Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53:549–554PubMedCrossRef

Barton CM, Staddon SL, Hughes CM, Hall PA, O’Sullivan C, Klöppel G, Theis B, Russell RCG, Neoptolemos J, Williamson RCN, Lane DP, Lemoine NR (1991) Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer 64:1076–1082PubMed

10.

Caldas C, Hahn SA, da Costa LT, Redson MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kem SE (1994) Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8:27–32PubMedCrossRef

11.

Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE (1996) DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271:350–353PubMedCrossRef

12.

Yatsuoka T, Sunamura M, Furukawa T, Fukushige S, Yokoyama T, Inoue H, Shibuya K, Takeda K, Matsuno S, Horii A (2000) Association of poor prognosis with loss of 12q, 17p, and 18q, and concordant loss of 6q/17p and 12q/18q in human pancreatic ductal adenocarcinoma. Am J Gastroenterol 95:2080–2085PubMedCrossRef

13.

Fukushige S, Furukawa T, Satoh K, Sunamura M, Kobari M, Koizumi M, Horii A (1998) Loss of chromosome 18q is an early event in pancreatic ductal tumorigenesis. Cancer Res 58:4222–4226PubMed

14.

Inoue H, Furukawa T, Sunamura M, Takeda K, Matsuno S, Horii A (2001) Exclusion of SMAD4 mutation as an early genetic change in human pancreatic ductal tumorigenesis. Genes Chromosomes Cancer 31:295–299PubMedCrossRef

15.

Schwarte-Waldhoff I, Volpert OV, Bouck NP, Sipos B, Hahn SA, Klein-Scory S, Luttges J, Kloppel G, Graeven U, Eilert-Micus C, Hintelmann A, Schmiegel W (2000) Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc Natl Acad Sci USA 97:9624–9629PubMedCrossRef

16.

Duda DG, Sunamura M, Lefter LP, Furukawa T, Yokoyama T, Yatsuoka T, Abe T, Inoue H, Motoi F, Egawa S, Matsuno S, Horii A (2003) Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells. Oncogene 22:6857–6864PubMedCrossRef

17.

Lefter LP, Furukawa T, Sunamura M, Duda DG, Takeda K, Kotobuki N, Oshimura M, Matsuno S, Horii A (2002) Suppression of the tumorigenic phenotype by chromosome 18 transfer into pancreatic cancer cell lines. Genes Chromosomes Cancer 34:234–242PubMedCrossRef

18.

Tanaka K, Oshimura M, Kikuchi R, Seki M, Hayashi T, Miyaki M (1991) Suppression of tumorigenicity in human colon carcinoma cells by introduction of normal chromosome 5 or 18. Nature 349:340–342PubMedCrossRef

19.

Padalecki SS, Johnson-Pais TL, Killary AM, Leach RJ (2001) Chromosome 18 suppresses the tumorigenicity of prostate cancer cells. Genes Chromosomes Cancer 30:221–229PubMedCrossRef

20.

Sun C, Yamato T, Furukawa T, Ohnishi Y, Kijima H, Horii A (2001) Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines. Oncol Rep 8:89–92PubMed

21.

Ishida M, Sunamura M, Furukawa T, Akada M, Fujimura H, Shibuya E, Egawa S, Unno M, Horii A (2007) Elucidation of the relationship of BNIP3 expression to gemcitabine chemosensitivity and prognosis. World J Gastroenterol 13:4593–4597PubMed

22.

van Golen KL, Wu ZF, Qiao XT, Bao L, Merajver SD (2000) RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res 60:5832–5838PubMed

23.

Hata T, Furukawa T, Sunamura M, Egawa S, Motoi F, Ohmura N, Marumoto T, Saya H, Horii A (2005) RNA interference targeting aurora kinase A suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res 65:2899–2905PubMedCrossRef

24.

Furukawa T, Kanai N, Shiwaku HO, Soga N, Uehara A, Horii A (2006) AURKA is one of the downstream targets of MAPK1/ERK2 in pancreatic cancer. Oncogene 25:4831–4839PubMedCrossRef

25.

Yamanaka S, Sunamura M, Furukawa T, Sun L, Lefter LP, Abe T, Yatsuoka T, Fujimura H, Shibuya E, Kotobuki N, Oshimura M, Sakurada A, Sato M, Kondo T, Matsuno S, Horii A (2004) Chromosome 12, frequently deleted in human pancreatic cancer, may encode a tumor suppressor gene that suppresses angiogenesis. Lab Invest 84:1339–1351PubMedCrossRef

26.

Tanaka K, Yanoshita R, Konishi M, Oshimura M, Maeda Y, Mori T, Miyaki M (1993) Suppression of tumorigenicity in human colon carcinoma cells by introduction of normal chromosome 1p36 region. Oncogene 8:2253–2258PubMed

27.

Kugoh H, Nakamoto H, Inoue J, Funaki K, Barrett JC, Oshimura M (2002) Multiple human chromosomes carrying tumor-suppressor functions for the mouse melanoma cell line B16F10, identified by microcell-mediated chromosome transfer. Mol Carcinog 35:148–156PubMedCrossRef

28.

Matsuura S, Tauchi H, Nakamura A, Kondo N, Sakamoto S, Endo S, Smeets D, Solder B, Belohradsky BH, Der Kaloustian VM, Oshimura M, Isomura M, Nakamura Y, Komatsu K (1998) Positional cloning of the gene for Nijmegen breakage syndrome. Nat Genet 19:179–181PubMedCrossRef

29.

Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, Tokino T, Taniguchi T, Tanaka N (2000) Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288:1053–1058PubMedCrossRef

30.

Seo YW, Shin JN, Ko KH, Cha JH, Park JY, Lee BR, Yun CW, Kim YM, Seol DW, Kim DW, Yin XM, Kim TH (2003) The molecular mechanism of Noxa-induced mitochondrial dysfunction in p53-mediated death. J Biol Chem 278:48292–48299PubMedCrossRef

31.

Schuler M, Maurer U, Goldstein JC, Breitenbucher F, Hoffarth S, Waterhouse NJ, Green DR (2003) p53 triggers apoptosis in oncogene-expressing fibroblasts by the induction of Noxa and mitochondrial Bax translocation. Cell Death Differ 10:451–460PubMedCrossRef

32.

Villunger A, Michalak EM, Coultas L, Mullauer F, Bock G, Ausserlechner MJ, Adams JP, Strasser A (2003) p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 302:1036–1038PubMedCrossRef

33.

Kim JY, Ahn HJ, Ryu JH, Suk K, Park JH (2004) BH3-only protein Noxa is a mediator of hypoxic cell death induced by hypoxia-inducible factor 1alpha. J Exp Med 199:113–124PubMedCrossRef

34.

Porta C, Hadj-Slimane R, Nejmeddine M, Pampin M, Tovey MG, Espert L, Alvarez S, Chelbi-Alix MK (2005) Interferons alpha and gamma induce p53-dependent and p53-independent apoptosis, respectively. Oncogene 24:605–615PubMedCrossRef

35.

Sun Y, Leaman DW (2005) Involvement of Noxa in cellular apoptotic responses to interferon, double-stranded RNA, and virus infection. J Biol Chem 280:15561–15568PubMedCrossRef

36.

Sasaki T, Sasahira T, Shimura H, Ikeda S, Kuniyasu H (2004) Effect of human Noxa on irinotecan-induced apoptosis in human gastric carcinoma cell lines. Hepatogastroenterology 51:912–915PubMed

37.

Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V, Bennett F, Pollock PM, Trent JM, Hendrix MJ, Rizzo P, Miele L, Nickoloff BJ (2005) Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 65:6282–6293PubMedCrossRef

38.

Fernandez Y, Verhaegen M, Miller TP, Rush JL, Steiner P, Opipari AW Jr, Lowe SW, Soengas MS (2005) Differential regulation of Noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res 65:6294–6304PubMedCrossRef

39.

Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D (2006) The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 107:257–264PubMedCrossRef

Titel: The PMAIP1 Gene on Chromosome 18 is a Candidate Tumor Suppressor Gene in Human Pancreatic Cancer
verfasst von: Masaharu Ishida
Makoto Sunamura
Toru Furukawa
Liviu P. Lefter
Rina Morita
Masanori Akada
Shinichi Egawa
Michiaki Unno
Akira Horii
Publikationsdatum: 01.09.2008
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 9/2008
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-007-0154-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2008

Elevated HbA1c Is an Independent Predictor of Aggressive Clinical Behavior in Patients with Colorectal Cancer: A Case-Control Study

Primary Culture of Pancreatic (Human) Acinar Cells

Is Oral l-Acyl-Carnitine an Effective Therapy for Hepatic Encephalopathy? Review of the Literature

Body Mass Index and the Efficacy of Acid-Mediating Agents for GERD

Scoring System for Predicting Response to Chemoradiotherapy, Including 5-Fluorouracil and Platinum, for Patients with Esophageal Cancer